NCT05320692Active, not recruitingPhase 3
A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma
A Phase III, Randomized, Open-Label, Multi-center Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) or TACE Alone in Patients With Incurable Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 11 Dec 2025
Brief summary (registry, in English)
A study to evaluate efficacy and safety of transarterial chemoembolization (TACE) in combination with Camrelizumab and Rivoceranib (Apatinib) therapy in patients with incurable hepatocellular carcinoma.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 423 (actual)
- First submitted
- 2 Apr 2022
- Start date
- 9 Aug 2022
- Primary completion date
- 30 Jul 2026
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT05320692
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 423
- From 9 Aug 2022 to the primary completion date, 30 Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Subjects who are ready for or have previously received organ or allogeneic bone marrow transplantation.
- Previous or current central nervous system metastasis.
- Thrombotic or embolic events occurred within 6 months prior to the start of study treatment.
- A history of gastrointestinal hemorrhage or a clear tendency to gastrointestinal bleeding within 6 months prior to the start of study treatment.
- Abdominal fistula, gastrointestinal perforation or abdominal abscess occurred within 6 months prior to the start of study treatment.
- Severe infection occurred within 4 weeks prior to the start of study treatment.
- Received live attenuated vaccine treatment within 28 days prior to the start of study treatment.
- Other investigational drugs were received within 28 days prior to the start of study treatment.
Other illness
- Has any active autoimmune disease or a history of autoimmune disease and may relapse.
- Suffering from hypertension and can not be well controlled by antihypertensive drugs.
- With clinical symptoms or diseases of the heart that are not well controlled.
- The subject has congenital or acquired immune deficiency (such as HIV infection).
- Known genetic or acquired bleeding or thrombotic tendencies.
Other
- Known hepatocholangiocarcinoma, sarcomatoid hepatocellular carcinoma, mixed cell carcinoma and lamellar cell carcinoma.
- Severe, unhealed or cracked wounds and active ulcers or untreated fractures.
- According to the assessment of investigator, the subject has other factors that may interfere with the results of the study or cause the forced termination of the study. Other protocol defined exclusion criteria could apply.
Who the study is looking for
- Voluntarily participate in this study and sign informed consent.
- Subjects diagnosed with HCC or clinically diagnosed with HCC by histopathology / cytology.
- Baseline imaging examination has at least one measurable lesion.
- Child-Pugh liver function rating was Grade A Within 7 days before randomization.
- ECOG PS score within 7 days before randomization: 0 or 1. Other protocol defined inclusion criteria could apply.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhongshan Hospital,Fudan University Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.